Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;4(6):1165-76.
doi: 10.2147/tcrm.s3094.

Treatment of severe psoriasis with infliximab

Ja Leman  1 , Ad Burden
Affiliations

Treatment of severe psoriasis with infliximab

Ja Leman et al. Ther Clin Risk Manag. 2008 Dec.

Abstract

Psoriasis is a chronic, immune mediated inflammatory disease characterized by increased cell signalling via cytokines and chemokines on a background of up-regulated gene expression. There is substantial evidence that psoriasis should be regarded as more than a cutaneous disease; major psychological morbidity and increased mortality from cardiovascular disease and cancer are increasingly recognized. Improved understanding of the genetic and immunological mechanisms underpinning psoriasis has occurred concurrently with the development of targeted biological therapies including infliximab. These newer therapeutic approaches can be very effective but their long term safety profile is not yet fully determined.

Keywords: co-morbidities; infliximab; pathogenesis; psoriasis; treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antoni C, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial. Arthritis Rheum. 2005a;52:1227–36. - PubMed
    1. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005b;64:1150–75. - PMC - PubMed
    1. Arnason BGW. The lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralisation in MS: results of a randomised. placebo controlled multicentre study. Neurology. 1999;53:457–65. - PubMed
    1. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immogenicity in rheumatoid arthritis patients treated with tumour necrosis factor alpha inhibitor infliximab. Arthritis Rhem. 2006;54:3782–89. - PubMed
    1. Benoit S, Toksoy A, Brocker EB, et al. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol. 2004;150:1009–12. - PubMed